Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.

× No keyword cloud information.

16 in total

1. Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors: Tze L Lai; Philip W Lavori
Journal: Stat Biosci Date: 2011-12

2. A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.

Authors: Nolan A Wages; Craig L Slingluff; Gina R Petroni
Journal: Contemp Clin Trials Date: 2015-01-29 Impact factor: 2.226

3. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Authors: Yong Zang; J Jack Lee; Ying Yuan
Journal: Clin Trials Date: 2014-06 Impact factor: 2.486

4. Advances in Statistical Approaches Oncology Drug Development.

Authors: Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal: Ther Innov Regul Sci Date: 2014-01 Impact factor: 1.778

5. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.

Authors: Nolan A Wages; Christopher Tait
Journal: J Biopharm Stat Date: 2014-06-06 Impact factor: 1.051

6. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.

Authors: Yong Zang; J Jack Lee
Journal: Stat Med Date: 2016-08-18 Impact factor: 2.373

Review 7. Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Authors: Anas Younes
Journal: Nat Rev Clin Oncol Date: 2010-12-14 Impact factor: 66.675

8. Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.

Authors: Elisabeth I Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun
Journal: J Biopharm Stat Date: 2009 Impact factor: 1.051

9. TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology.

Authors: Wentian Guo; Yang Ni; Yuan Ji
Journal: Stat Biosci Date: 2015-06-30

Review 10. Treatment of pediatric brain tumors.

Authors: Matthias Karajannis; Jeffrey C Allen; Elizabeth W Newcomb
Journal: J Cell Physiol Date: 2008-12 Impact factor: 6.384